Monocyte‐mediated metabolic rewiring via CD31‐CD38 interactions promotes growth and drug‐resistance in multiple myeloma
HemaSphere · 2026-04 · 10 (4)
DOI: 10.1002/hem3.70358 ↗At a glance
Journal article in HemaSphere, published online on 2026-04-16. Written by Ramin Raoof and 18 co-authors. Institution: Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunology Cancer Immunology Amsterdam The Netherlands. 86 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Janssen Pharmaceuticals.
Abstract (original language)
Multiple myeloma (MM) cells interact with different components of the bone marrow (BM) microenvironment, which plays a critical role in MM progression and confers resistance to therapy. Here, we report that monocytes actively control MM cell metabolism by transferring mitochondria to MM cells, thereby increasing their mitochondrial content. Transfer of mitochondria required the expression of CD38 on the surface of MM cells and its ligand CD31 (PECAM‐1) on monocytes. The mitochondrial increase in MM cells induced a boost in oxidative phosphorylation (OXPHOS). This monocyte‐mediated metabolic adjustment promoted growth, motility, and drug‐resistance in both MM cell lines and primary MM cells. Notably, the CD38‐targeting monoclonal antibody daratumumab prevented mitochondrial transfer via blocking CD38 on MM cells. Furthermore, in the presence of daratumumab, monocytes acquired a divergent role and obtained mitochondria from MM cells through the process of trogocytosis. Daratumumab‐mediated disruption of mitochondrial transfer reduced the mitochondrial content in MM cells, prevented the boost in OXPHOS, significantly impaired MM cell growth and migration, and mitigated drug‐resistance. In conclusion, we reveal a crucial metabolic interplay between monocytes and MM cells within the BM microenvironment that promotes tumor growth and induces therapy resistance, providing the rationale for treatment strategies that combine targeting tumor metabolism with existing anti‐MM agents.
Authors and institutions
- Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunology Cancer Immunology Amsterdam The Netherlands.
- Department of Hematology Amsterdam UMC location Vrije Universiteit Amsterdam Amsterdam The Netherlands.
- Department of Experimental Immunology Amsterdam UMC location University of Amsterdam Meibergdreef 9 Amsterdam The Netherlands.
- Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands.
- Janssen Research & Development Spring House Pennsylvania USA.
- Lymphoma and Myeloma Center Amsterdam (LYMMCARE) Amsterdam The Netherlands.
ORCID profiles: Ramin Raoof, Giada Dal Collo, Charlotte L B M Korst, Wassilis S C Bruins, Arnon P Kater, Niels W C J van de Donk
Funding
- Janssen Pharmaceuticals
Cite
APA
Raoof, R., Dal Collo, G., Simon-Molas, H., Tzortzi, P., Kulaj, K., Demirez, E. N., Massaro, C., Poels, R., Korst, C. L. B. M., O'Neill, C. A., Bruins, W. S. C., Broekmans, M. E. C., Behradkia, P., Krevvata, M., Zweegman, S., Kater, A. P., Baglio, S. R., Mutis, T., & van de Donk, N. W. C. J. (2026). Monocyte‐mediated metabolic rewiring via CD31‐CD38 interactions promotes growth and drug‐resistance in multiple myeloma. HemaSphere, 10(4). https://doi.org/10.1002/hem3.70358
Vancouver
Raoof R, Dal Collo G, Simon-Molas H, Tzortzi P, Kulaj K, Demirez EN, et al. Monocyte‐mediated metabolic rewiring via CD31‐CD38 interactions promotes growth and drug‐resistance in multiple myeloma. HemaSphere. 2026;10(4). doi:10.1002/hem3.70358
BibTeX
@article{Raoof2026,
author = {Raoof, Ramin and Dal Collo, Giada and Simon-Molas, Helga and Tzortzi, Panagiota and Kulaj, Konxhe and Demirez, Elif N and Massaro, Crescenzo and Poels, Renée and Korst, Charlotte L B M and O'Neill, Chloe A and Bruins, Wassilis S C and Broekmans, Marloes E C and Behradkia, Payam and Krevvata, Maria and Zweegman, Sonja and Kater, Arnon P and Baglio, Serena R and Mutis, Tuna and van de Donk, Niels W C J},
title = {Monocyte‐mediated metabolic rewiring via CD31‐CD38 interactions promotes growth and drug‐resistance in multiple myeloma},
journal = {HemaSphere},
year = {2026},
volume = {10},
number = {4},
doi = {10.1002/hem3.70358}
}
EUVIMED